Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
J Infect Dis. 2020 Nov 9;222(11):1837-1842. doi: 10.1093/infdis/jiaa294.
AIDS Clinical Trials Group study A5308 found reduced T-cell activation and exhaustion in human immunodeficiency virus (HIV) controllers start antiretroviral therapy (ART). We further assessed HIV-specific T-cell responses and post-ART viral loads. Before ART, the 31% of participants with persistently undetectable viremia had more robust HIV-specific T-cell responses. During ART, significant decreases were observed in a broad range of T-cell responses. Eight controllers in A5308 and the Study of the Consequences of the Protease Inhibitor Era (SCOPE) cohort showed no viremia above the level of quantification in the first 12 weeks after ART discontinuation. ART significantly reduced HIV-specific T-cell responses in HIV controllers but did not adversely affect controller status after ART discontinuation.
艾滋病临床研究小组 A5308 研究发现，艾滋病毒（HIV）感染者在开始接受抗逆转录病毒治疗（ART）时，T 细胞的激活和耗竭减少。我们进一步评估了 HIV 特异性 T 细胞反应和 ART 后的病毒载量。在开始 ART 之前，持续检测不到病毒血症的参与者中有 31%具有更强的 HIV 特异性 T 细胞反应。在 ART 期间，观察到广泛的 T 细胞反应显著下降。A5308 研究和蛋白酶抑制剂时代后果研究（SCOPE）队列中的 8 名控制者在 ART 停药后 12 周内，病毒载量未超过定量检测水平。ART 显著降低了 HIV 控制者的 HIV 特异性 T 细胞反应，但在 ART 停药后并未对控制者的状况产生不利影响。
